At a Glance
- Company: Parabilis Medicines
- Funding to date: ~$800 million
- Focus area: Targeting “undruggable” cancer proteins
- Strategy: Novel peptide-based therapeutics
- Next steps: IPO filing and public market debut
What happened?
Parabilis Medicines has publicly disclosed plans to pursue an initial public offering, marking its transition toward the public markets. The company has previously raised around $800 million in private funding to support its drug discovery platform.
Why does it matter?
The IPO signals investor confidence in approaches targeting proteins that have historically been difficult to drug. Success in this area could unlock new classes of cancer therapies and expand the range of treatable targets.
Who’s behind it?
Parabilis Medicines, formerly known as FogPharma, is developing stabilised peptide-based drugs designed to penetrate cells and modulate intracellular protein interactions. The company has attracted significant backing from major biotech investors.
How was it achieved?
Parabilis built its platform around Helicon peptides, which are engineered to bind intracellular targets with high specificity. Strong fundraising and partnerships—such as its collaboration with Regeneron—have helped position the company for a public offering.
What’s next?
The company will proceed with IPO preparations, including regulatory filings and investor roadshows. Proceeds are expected to fund clinical development of its pipeline and further expansion of its platform targeting “undruggable” biology.